Skip to main content
EnglishEnglish
EnglishEnglishArabicArabicChinese (Simplified)Chinese (Simplified)FrenchFrenchGermanGermanHindiHindiPortuguesePortugueseRussianRussianSpanishSpanishSwahiliSwahili

Header

  • Contact us
  • Subscribe to newsletter
Home The Task Force for Global Health logo
  • https://twitter.com/GlobalHep
  • https://www.facebook.com/GlobalHep/
  • https://www.linkedin.com/company/coalition-for-global-hepatitis-elimination
Donate
Add a Program
Add a Program
Profile
Logout

Main navigation

  • About
    • Who we are
    • What we do
    • Our team
    • Technical Advisory Board
    • Executive Board
    • Donor Acknowledgements
    • CGHE Annual Reports
      • Annual Report 2022
      • Annual Report 2021
      • Annual Report 2020
    • CGHE Publications
  • Partner programs
    • Programs search
  • Data dashboards
    • Country data dashboards
    • National Hepatitis Elimination Profiles
  • Evidence base
    • All evidence (search)
      • Evidence Base Methodology
    • HCV Treatment in Pregnancy
      • Tip-HepC Registry
      • TiP-HepC Systematic Review Results
    • Action Plan Systematic Review
    • Hepatitis B Birth Dose Vaccine Systematic Review
      • Synthesis Brief of Hepatitis B Birth Dose Evidence Base
    • HCV Testing Systematic Review
    • COVID-19 Evidence Hub
      • COVID-19 and Liver Disease Synthesis
      • Clinical Liver Disease COVID-19 special series
        • The COVID-19 Pandemic: An Epidemiologic, Public Health, and Clinical Brief
        • Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID-19 Pandemic
    • Innovations in Hepatitis Elimination (CLD Series)
      • Author Interviews
      • Introduction to Series
      • Past Publications
      • Author Guidance
    • Hepatitis Elimination Help Desk
  • Resources
    • Hep C Elimination Tool
      • Access the Tool
      • User Guide
      • Frequently Asked Questions
    • Search resources
    • Technical Assistance Help Desk and Frequently Asked Questions
    • Toolkit: Birth Dose Vaccination in Africa
  • Elimination champions
    • Nominations for Elimination Champions
  • Webinars & Events
    • Hep Test
    • Linkage to care
    • Strategic Information Collaborative
    • Regional Hepatitis Elimination
    • HepB Birth Dose Introduction in AFRO
    • Innovations in Hepatitis Elimination
    • NIH "Moving from Hepatitis Discovery to Elimination"
    • Search webinars
    • Treatment of HCV in Pregnancy for Hepatitis (TiP-HepC)
      • Webinar 1: Challenges
      • Webinar 2: Strategies
  • News
    • Announcements
    • Blog
    • Elimination Champions
    • Events
    • Newsletters
    • Press releases
    • Publications
    • News search
  • UN Group of Friends
  1. Home
  2. Evidence base
  3. Evidence base search

Evidence base articles search

The evidence base was developed using rigorous review methods for the identification and quality assessment of eligible systematic reviews and guideline and policy documents. In response to identified global research priorities, the evidence base currently presents characteristics of interventions to inform implementation of hepatitis B birth dose , HCV testing and hepatitis B and C action plans. Updates to the evidence base are planned to address subsequent priorities.

Edit

Evidence base search

Filter

  • Action plan
  • Birth dose
  • HCV testing
  • HCV treatment in pregnancy ("Tip-HepC")
  • Hepatitis B
  • Hepatitis C
  • Coinfection with HIV
  • Community mobilization
  • Harm reduction
  • HBV testing and linkage to care
  • HCV testing and linkage to Care
  • HCV treatment
  • Hepatitis B Vaccination
  • Hep B birth-dose vaccination
  • Implementation of birth dose vaccination
  • Implementation of vaccination (general)
  • Linkage to care
  • Persons who inject drugs: Medication assisted therapy
  • Prevention mother-child transmission
  • Prophylaxis
  • Safer injection practices
  • Safer sex practices
  • Screening and diagnosis
  • Screening of pregnant women
  • Strategic data analysis
  • Testing
  • Treatment
  • Treatment (direct or referral)
  • Vaccination (general)
  • Adolescents (10 - 19 years of age)
  • Adults
  • Adults (> 19 years of age)
  • All ages
  • Birth cohorts of adults
  • Blood transfusion recipients
  • Children (> one year < 10 years of age)
  • Children 5-11
  • Children 12-17
  • Children Under 5
  • Dialysis patients
  • General Population
  • Immigrants/Refugees
  • Incarcerated populations (current and former)
  • Individuals with blood disorders
  • Infants (less than one year of age)
  • Men who have sex with men
  • Newborn (born in last 30 days)
  • Newborns
  • People experiencing homelessness
  • Persons who inject drugs
  • Persons with substance use disorder
  • Pregnant women
  • Young Adults <21
  • Country
  • Global
  • Local (City or community)
  • Region
  • State/Province
  • Case-control
  • Case report
  • Clinical practice guideline
  • Cost-effective analysis
  • Cross-sectional
  • Decision analytic model
  • Guidance
  • Guideline
  • Laboratory study
  • Mathematical modelling
  • Meta-Analysis
  • Narrative Review
  • Network Meta-analysis
  • Prospective cohort
  • Randomized control trial
  • Recommendations
  • Retrospective chart review
  • Retrospective cohort
  • Systematic Review
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Central African Republic
  • Chad
  • Chile
  • China
  • Colombia
  • Comoros
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • Ecuador
  • Egypt
  • El Salvador
  • England
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • European Union
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Global
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran (Islamic Republic of)
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea (Republic of)
  • Kuwait
  • Kyrgyzstan
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russian Federation
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Scotland
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Tajikistan
  • Tanzania
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States of America
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Viet Nam
  • Yemen
  • Zambia
  • Zimbabwe
  • African Region
  • Eastern Mediterranean Region
  • European Region
  • Region of the Americas
  • South-East Asia Region
  • Western Pacific Region
  • 2002
  • 2004
  • 2005
  • 2006
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • Laboratory-based antibody test
  • Laboratory-based antibody test,Laboratory-based HCV core antigen (cAg) confirmatory test
  • Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test
  • Laboratory-based antibody test, Point-of-care PCR/RNA test
  • Laboratory-based HCV core antigen (cAg) confirmatory test
  • Laboratory-based PCR/RNA (confirmatory) test
  • Point-of-care antibody test (rapid test)
  • Point-of-care antibody test (rapid test), Laboratory-based PCR/RNA (confirmatory) test
  • Point-of-care antibody test (rapid test), Point-of-care PCR/RNA test
  • Point-of-care antibody test (rapid test), Laboratory-based HCV core antigen (cAg) confirmatory test
  • Point-of-care PCR/RNA test
Displaying 1 - 12 of 413
  • National Strategic Framework on Viral Hepatitis in Nigeria 2022-2030

    2022

    Nigeria Federal Ministry of Health

  • National Hepatitis C Action Plan for Aotearoa New Zealand Māhere Mahi mō te Ate Kakā C 2020–2030

    2021

    New Zealand Ministry of Health

  • Michigan’s State Plan on Eliminating Hepatitis C

    2021

    Michigan Department of Health + Human Services

  • Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021-2025)

    2020

    U.S. Department of Health and Human Services

  • Strategy for the elimination of hepatitis C in Cantabria

    2020

    Crespo J, Tejerina Puente A, Cuadrado A, Llerena S, Cabezas J, Work Group for the elimination of hepatitis C in Cantabria. Strategy for the Elimination of Hepatitis C in Cantabria. Rev Esp Enferm Dig 2020;112(7):565-570

  • Hep Free 2030: The Hawai'i Hepatitis Elimination Strategy 2020-2030

    2020

    Hep free Hawai'i

  • End Hep C SF Strategic Plan 2020-2022

    2020

    End Hep C SF (San Francisco)

  • Accelerating our response - Government of Canada Five-year Action Plan on Sexually Transmitted and Blood-borne Infections

    2019

    Government of Canada

  • Blueprint to Inform Hepatitis C Elimination Efforts in Canada: What do service providers need to know?

    2019

    Canadian Network on Hepatitis C

  • Hep C Free Washington: Plan to Eliminate Hepatitis C in Washington State by 2030-- United States

    2019

    Hep C Free Washington

  • Hepatitis C in England 2019: Working to eliminate hepatitis C as a major public health threat

    2019

    Public Health England

  • Malaysia National Strategic Plan for Hepatitis B and C 2019-2023

    2019

    Ministry of Health Malaysia

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page ››
  • Last page Last »

Contact us

globalhep [at] taskforce.org

Tel: +1-404-371-0466

 

Photos on home page by Tayvessa Wilson, Conor Ashleigh, and Zunaid Murshed Paiker

Support us

Donate

Follow us

  • https://twitter.com/GlobalHep
  • https://www.facebook.com/GlobalHep/
  • https://www.linkedin.com/company/coalition-for-global-hepatitis-elimination

Sign up to our newsletter

<

Footer

  • Contact
© 2019 - 2023 Coalition for Global Hepatitis Elimination
Website by Manta Ray Media
q